Crossmark Global Holdings Inc. Has $1.83 Million Stock Holdings in DaVita Inc. (NYSE:DVA)

Crossmark Global Holdings Inc. decreased its holdings in shares of DaVita Inc. (NYSE:DVAFree Report) by 24.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,500 shares of the company’s stock after selling 5,631 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in DaVita were worth $1,833,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in DVA. Deutsche Bank AG lifted its holdings in DaVita by 421.8% during the 3rd quarter. Deutsche Bank AG now owns 1,095,081 shares of the company’s stock valued at $103,518,000 after purchasing an additional 885,195 shares during the last quarter. Norges Bank acquired a new stake in DaVita during the 4th quarter valued at $36,626,000. Invesco Ltd. lifted its holdings in DaVita by 21.3% during the 3rd quarter. Invesco Ltd. now owns 1,667,255 shares of the company’s stock valued at $157,606,000 after purchasing an additional 292,767 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its holdings in DaVita by 148.8% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 365,701 shares of the company’s stock valued at $34,570,000 after purchasing an additional 218,693 shares during the last quarter. Finally, Allianz Asset Management GmbH lifted its holdings in shares of DaVita by 63.9% during the fourth quarter. Allianz Asset Management GmbH now owns 548,642 shares of the company’s stock worth $57,476,000 after buying an additional 213,992 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

Insider Buying and Selling

In other DaVita news, Director Barbara J. Desoer sold 5,030 shares of DaVita stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $138.81, for a total value of $698,214.30. Following the transaction, the director now owns 10,954 shares in the company, valued at $1,520,524.74. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.00% of the stock is owned by company insiders.

DaVita Stock Down 0.6 %

Shares of NYSE DVA opened at $143.03 on Friday. The company has a debt-to-equity ratio of 7.95, a quick ratio of 1.37 and a current ratio of 1.43. DaVita Inc. has a 52 week low of $71.51 and a 52 week high of $147.93. The stock has a market capitalization of $12.54 billion, a P/E ratio of 16.25, a PEG ratio of 1.10 and a beta of 0.96. The stock’s fifty day moving average is $136.69 and its 200 day moving average is $122.22.

DaVita (NYSE:DVAGet Free Report) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $2.38 EPS for the quarter, topping analysts’ consensus estimates of $1.95 by $0.43. DaVita had a return on equity of 68.52% and a net margin of 6.61%. The company had revenue of $3.07 billion for the quarter, compared to analysts’ expectations of $3.03 billion. During the same quarter last year, the business earned $1.58 earnings per share. DaVita’s revenue was up 6.9% on a year-over-year basis. Sell-side analysts forecast that DaVita Inc. will post 9.62 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on DVA. Barclays lifted their target price on DaVita from $133.00 to $150.00 and gave the stock an “equal weight” rating in a report on Monday, May 6th. UBS Group lifted their target price on DaVita from $113.00 to $134.00 and gave the stock a “buy” rating in a report on Wednesday, February 14th. Truist Financial lifted their target price on DaVita from $135.00 to $150.00 and gave the stock a “hold” rating in a report on Wednesday, May 15th. Finally, StockNews.com downgraded DaVita from a “strong-buy” rating to a “buy” rating in a report on Saturday. Two analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, DaVita has a consensus rating of “Moderate Buy” and an average price target of $144.67.

Get Our Latest Stock Analysis on DVA

DaVita Company Profile

(Free Report)

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

Read More

Institutional Ownership by Quarter for DaVita (NYSE:DVA)

Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.